LabCorp Clinical Trials selected as preferred provider by BMS
Laboratory Corporation of America Holdings (LabCorp) announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb.
The five-year agreement builds on a long-standing partnership between the two companies during which LabCorp's global central lab, biomarker and specialty testing capabilities have supported various Bristol-Myers Squibb early and late-stage clinical development programs.
"We are excited to expand our relationship with Bristol-Myers Squibb to provide a more flexible and integrated approach to laboratory testing services in support of their innovative clinical development pipeline," said Dr. Mark Brecher, chief medical officer, LabCorp.